Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSI NYSEMKT:IGC NASDAQ:KYTX NASDAQ:MIST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$10.93-0.4%$11.30$8.06▼$16.50$149.52M1.6641,997 shs22,521 shsIGCIGC Pharma$0.43+32.5%$0.37$0.25▼$0.48$39.77M1.08913,992 shs214,616 shsKYTXKyverna Therapeutics$3.94+8.5%$3.58$1.78▼$7.85$156.98M3.08281,531 shs217,394 shsMISTMilestone Pharmaceuticals$1.80+1.1%$1.71$0.63▼$2.75$151.29M0.61.02 million shs791,219 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-0.36%-4.79%-9.67%+13.15%-18.62%IGCIGC Pharma-0.92%+0.70%+26.69%+40.26%+27.06%KYTXKyverna Therapeutics+8.54%+6.20%+18.32%+16.22%-47.11%MISTMilestone Pharmaceuticals+1.12%-2.17%+17.65%+4.05%+20.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$10.93-0.4%$11.30$8.06▼$16.50$149.52M1.6641,997 shs22,521 shsIGCIGC Pharma$0.43+32.5%$0.37$0.25▼$0.48$39.77M1.08913,992 shs214,616 shsKYTXKyverna Therapeutics$3.94+8.5%$3.58$1.78▼$7.85$156.98M3.08281,531 shs217,394 shsMISTMilestone Pharmaceuticals$1.80+1.1%$1.71$0.63▼$2.75$151.29M0.61.02 million shs791,219 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences-0.36%-4.79%-9.67%+13.15%-18.62%IGCIGC Pharma-0.92%+0.70%+26.69%+40.26%+27.06%KYTXKyverna Therapeutics+8.54%+6.20%+18.32%+16.22%-47.11%MISTMilestone Pharmaceuticals+1.12%-2.17%+17.65%+4.05%+20.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 3.00Buy$42.00284.26% UpsideIGCIGC Pharma 3.00Buy$3.88796.99% UpsideKYTXKyverna Therapeutics 3.14Buy$16.60321.32% UpsideMISTMilestone Pharmaceuticals 2.25Hold$5.00177.78% UpsideCurrent Analyst Ratings BreakdownLatest IGC, MIST, GLSI, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $10.008/20/2025GLSIGreenwich LifeSciencesNoble FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/20/2025KYTXKyverna TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AIGCIGC Pharma$1.33M29.56N/AN/A$0.08 per share5.40KYTXKyverna Therapeutics$7.03M24.24N/AN/A$6.17 per share0.64MISTMilestone Pharmaceuticals$1M152.98N/AN/A$0.25 per share7.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$15.79M-$1.36N/AN/AN/AN/A-700.90%-455.64%11/13/2025 (Estimated)IGCIGC Pharma-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/AKYTXKyverna Therapeutics-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)MISTMilestone Pharmaceuticals-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%11/11/2025 (Estimated)Latest IGC, MIST, GLSI, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025GLSIGreenwich LifeSciences-$0.24-$0.30-$0.06-$0.30N/AN/A8/12/2025Q2 2025KYTXKyverna Therapeutics-$1.00-$0.97+$0.03-$0.97N/AN/A8/12/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18-$0.20-$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A1.851.85IGCIGC Pharma0.021.150.98KYTXKyverna TherapeuticsN/A5.395.39MISTMilestone Pharmaceuticals4.064.974.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%IGCIGC Pharma3.87%KYTXKyverna Therapeutics18.08%MISTMilestone Pharmaceuticals86.18%Insider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.67%IGCIGC Pharma23.66%KYTXKyverna Therapeutics22.00%MISTMilestone Pharmaceuticals19.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences313.63 million6.59 millionNot OptionableIGCIGC Pharma6190.81 million54.60 millionN/AKYTXKyverna Therapeutics9643.25 million33.73 millionOptionableMISTMilestone Pharmaceuticals3084.99 million68.42 millionOptionableIGC, MIST, GLSI, and KYTX HeadlinesRecent News About These CompaniesPropel Bio Management LLC Acquires New Stake in Milestone Pharmaceuticals Inc. $MISTSeptember 2, 2025 | marketbeat.comStonepine Capital Management LLC Reduces Stock Holdings in Milestone Pharmaceuticals Inc. $MISTAugust 26, 2025 | marketbeat.comMilestone® Pharmaceuticals to Present at Upcoming ConferencesAugust 19, 2025 | globenewswire.comResearch Analysts Set Expectations for MIST Q3 EarningsAugust 17, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Posts Earnings Results, Misses Expectations By $0.02 EPSAugust 14, 2025 | marketbeat.comMilestone Pharmaceuticals Advances CARDAMYST with FDA and Financial BoostAugust 13, 2025 | theglobeandmail.comMilestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)August 12, 2025 | msn.comMilestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateAugust 12, 2025 | globenewswire.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Sold by Alta Fundamental Advisers LLCAugust 11, 2025 | marketbeat.comMilestone Pharmaceuticals (MIST) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Kestra Medical Technologies Ltd. (KMTS) and Milestone Pharmaceuticals (MIST)July 18, 2025 | theglobeandmail.comMilestone Pharmaceuticals Remains A Buying Opportunity Despite Recent DilutionJuly 18, 2025 | seekingalpha.comMilestone Pharmaceuticals Announces Public Offering for $48.7MJuly 16, 2025 | theglobeandmail.comTD Cowen Sticks to Its Hold Rating for Milestone Pharmaceuticals (MIST)July 16, 2025 | theglobeandmail.comUS FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal sprayJuly 14, 2025 | pharmabiz.comPMilestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJJuly 11, 2025 | wsj.comMilestone says heart disorder therapy under FDA review againJuly 11, 2025 | msn.comMilestone Pharmaceuticals stock plunges on public offering announcementJuly 11, 2025 | au.investing.comMilestone Pharmaceuticals Shares Drop Sharply After Public Offering AnnouncementJuly 11, 2025 | msn.comWhy Is Milestone Pharmaceuticals Stock Plunging On Friday?July 11, 2025 | benzinga.comCrude Oil Rises Sharply; Milestone Pharmaceuticals Shares PlungeJuly 11, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Smaller Industrials Names Seeing Surging Growth: Here's WhyBy Nathan Reiff | August 30, 2025IGC, MIST, GLSI, and KYTX Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$10.93 -0.04 (-0.36%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$10.92 -0.01 (-0.09%) As of 09/5/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.IGC Pharma NYSEMKT:IGC$0.43 +0.11 (+32.47%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$0.43 0.00 (0.00%) As of 09/5/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Kyverna Therapeutics NASDAQ:KYTX$3.94 +0.31 (+8.54%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.94 0.00 (0.00%) As of 09/5/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Milestone Pharmaceuticals NASDAQ:MIST$1.80 +0.02 (+1.12%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.80 +0.00 (+0.28%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
